Lead For Cannabis Products At The FDA Patrick Cournoyer We've Been On A Fact-Finding Mission Since 2018-2019; We Would Go Through The Process If CBD Could Meet The Other Applicable Provisions Of The Food Drug And Cosmetic Act For Dietary Supplements
Portfolio Pulse from Benzinga Newsdesk
Patrick Cournoyer, the lead for cannabis products at the FDA, stated that the agency has been on a fact-finding mission since 2018-2019 to determine if CBD could meet the provisions of the Food Drug and Cosmetic Act for dietary supplements.
September 28, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The news may indirectly impact MSOS, an ETF that tracks the performance of US-listed companies involved in the cannabis industry. Regulatory clarity on CBD could influence these companies' operations.
While MSOS is not directly mentioned, it tracks US-listed cannabis companies. The FDA's ongoing assessment of CBD as a dietary supplement could influence the regulatory environment these companies operate in, potentially impacting their performance and, by extension, MSOS's value.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50